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STRUCTURED ABSTRACT (240 words) 
Context. The Stages of Reproductive Aging Workshop proposed bleeding and hormonal 
criteria for the menopausal transition, but operational definitions of hormone parameters 
were not specified. Objective. This paper investigates the longitudinal relationship of 
annual serum follicle-stimulating hormone (FSH) levels with four proposed bleeding 
criteria for the late menopausal transition in two cohort studies. The goal is to provide 
empirically-based guidance regarding application of hormonal criteria that may be 
optimal for widespread application in clinical and research settings for assessing 
menopausal stage. 
Design/Setting. Prospective menstrual calendar and annual serum FSH data from two 
population-based cohort studies: the Melbourne Women’s Midlife Health 
Project(MWMHP) and the Study of Women’s Health Across the Nation(SWAN).  
Participants: 189 MWMHP and 2256 SWAN women aged 42-57 at baseline who 
contributed >=10 menstrual cycles and at least one annual serum FSH value.  
Main Outcome Measure(s). Association between bleeding criteria for the late 
menopausal transition and FSH. Association of bleeding criteria, FSH, and hot flashes 
with the final menstrual period. 
Results. A single FSH measure is an independent marker of the late menopausal 
transition, but FSH concentrations are less predictive of menopausal stage than any of 
four proposed bleeding criteria. Criterion FSH values for the late transition are similar 
across both studies. Experience of hot flashes adds no information in the presence of 
hormonal and bleeding criteria.  
Conclusions. An annual serum FSH concentration of 40 IU/L could be incorporated, in 
conjunction with bleeding markers, into the STRAW paradigm for markers of the late 
menopausal transition. 
INTRODUCTION  
Both clinical management and investigation of the menopausal transition have 
been hampered by the lack of a well-characterized and validated biomarker of the 
evolution of ovarian function from active reproduction to a post-reproductive state. 
Rigorous descriptions of this transition have relied primarily on progressive changes in 
menstrual bleeding patterns (1-6) to describe and relate the reproductive aging process to 
other endpoints of interest. Follicle-stimulating hormone, a glycoprotein dimer secreted 
by the anterior pituitary, has emerged as a readily and reproducibly measurable potential 
marker (7) but has suffered to date by a lack of precision with respect to other markers of 
the menopausal transition, particularly the final menstrual period (FMP) which is 
classically used to define menopause (8). 
  The need for a rigorous characterization of the menopausal transition to both 
standardize terminology and criteria for investigational purposes and to inform women 
and their care providers prompted the Stages of Reproductive Aging Workshop 
(STRAW) in July, 2001 (9) which resulted in a seven stage classification of female 
reproductive life based on the best available evidence. The proposed STRAW paradigm 
included bleeding, symptom and hormonal criteria, but operational definitions of 
hormone parameters were not included because insufficient information was available to 
establish definitive criteria. Consensus was reached that, of the candidate biomarkers of 
the transition, FSH was the best available and STRAW recommended that specific 
criteria be developed for incorporating FSH into the evolving system for staging 
reproductive aging (9). Vasomotor symptoms, including hot flashes, although 
characteristic of the menopausal transition, are not experienced by all women and are not 
considered essential criteria within the staging system. 
 The ReSTAGE collaboration is conducting an empirical evaluation of proposed 
criteria for staging reproductive aging in the context of the natural history of the 
menopausal transition. In a previous paper (10) we assessed proposed bleeding criteria 
for the late menopausal transition using prospectively collected menstrual calendar data 
from four large cohort studies : TREMIN (11), the Melbourne Women’s Midlife Health 
Project (MWMHP) (1), the Seattle Midlife Women’s Health Study  (SMWHS) (3), and 
the multi-site, multi-ethnic, Study of Women’s Health Across the Nation (SWAN) (4). 
Although our findings supported STRAW’s recommendation that amenorrhea of 60-days 
be used as the bleeding criterion for the late transition, a correlation between this criterion 
and underlying hormonal changes and symptoms has yet to be demonstrated.  Annual 
serum FSH levels are available from MWMHP and SWAN and the assays have been 
cross-validated to allow comparability. This paper investigates the longitudinal 
relationship of annual serum FSH with four proposed bleeding markers of the late 
menopausal transition.  Our underlying goal is to address the question: Does information 
on serum FSH and hot flashes improve the determination of a woman’s entry into the late 
menopausal transition as compared to the use of bleeding criteria for the late menopausal 
transition alone? 
 
EXPERIMENTAL SUBJECTS 
  This study has been approved by Institutional Review Boards at the Universities 
of Michigan, Washington, Massachusetts and Melbourne. For this paper, we conducted 
secondary analyses using menstrual calendar information, annual serum FSH 
concentrations, and self report of hot flashes accumulated in two longitudinal cohort 
studies of the menopausal transition. 
 
The Melbourne Women’s Midlife Health Project (MWMHP) began in 1991 with a 
cross-sectional survey of 2001 mid-aged Australian-born women of Anglo-European 
heritage identified by random telephone digital dialing (response rate=71%) (12). From 
these women the MWMHP enrolled 438 women, aged 45 -55 years, who had menstruated 
in the prior 3 months and were not using hormone therapy into a longitudinal study 
(response rate=56%). This analysis includes records from the 189 women who maintained 
menstrual records through at least 10 untreated bleeding segments and provided at least 
one untreated serum sample for FSH measurement. (The term bleeding segment is 
analogous to menstrual cycle but acknowledges that menstrual calendar data cannot 
distinguish menstrual from nonmenstrual bleeds.) 
 
The Study of Women’s Health Across the Nation (SWAN) is an ongoing multi-
ethnic, multi-site longitudinal community-based study of mid-aged women begun in 1995 
(4).  A cross-sectional survey randomly selected women aged 40-55 years from a variety 
of lists including a large managed health care plan, community census, utility households, 
and registered voters, or by random digit dialing. Each site then recruited about 450 
women including Caucasian women and women from one minority group (African 
Americans at four sites; and Japanese, Chinese, and Hispanic women at one site each). 
Eligibility requirements for the longitudinal cohort included age 42-52 years, an intact 
uterus, no reproductive hormones use at time of enrollment and at least one menstrual 
period in the previous 3 months. A total of 3302 women were enrolled. This analysis 
includes records of the 2256 women who maintained menstrual records through at least 
10 untreated segments and provided at least one untreated serum sample for FSH 
measurement. 
 
MATERIALS AND METHODS 
Both studies included a menstrual calendar and asked women to record menstrual 
bleeding on each day bleeding occurred. Although slightly different in format, calendars 
identified the date of bleeding onset and days of bleeding in a comparable manner. 
Ascertainments of the onset of the late transition and of the final menstrual period (FMP) 
are based on the menstrual calendar data. 
  
In MWMHP, each menstrual calendar card covered one year. Participants were 
followed up to 10 years with annual assessments which included symptoms, measured 
body mass index (BMI), smoking history, hormone use, and blood sampling to measure 
FSH.  Experience of hot flashes was obtained from the North American symptom 
checklist (13). Fasting morning blood samples for hormone assays were taken between 
days 4 and 8 of the menstrual cycle for those still cycling, or after 3 months of 
amenorrhea as previously described (14). FSH was measured initially by 
radioimmunoassay (RIA) in year one (7).   Two subsequent changes in method were 
used, the automated Microparticulate Enzyme Immunoassay (Abbott Diagnostics IMX 
Analyser Chicago, IL, USA) (years 2 and 3) and for all samples from year 4 onwards, the 
TOSOH AIA1200 automated Enzyme Immunoassay.  Correlation coefficients were: FSH 
(IMX) and RIA, 0.98, and FSH (TOSOH) with IMX 0.99.  Inter- and intra-assay 
coefficients of variation were 5.4 % and 4.0 %, respectively. 
 
In SWAN, women were provided monthly menstrual calendars. Assessments at 
baseline and annual follow-up visits included symptoms, measured BMI, smoking 
history, hormone use, and blood sampling to measure FSH. Blood was drawn between 
days 2-5 of the follicular phase of the menstrual cycle in regularly cycling women. Serum 
was frozen at -80 degrees Centigrade and sent on dry-ice to the SWAN Endocrine 
Laboratory at the University of Michigan. Hormone assays were conducted using an 
ACS-180 automated analyzer (Bayer Diagnostics Corp, 115 Norwood Park South, 
Norwood, MA. 02062-4658).  Serum FSH concentrations were measured with a two-site 
chemiluminometric immunoassay that uses constant amounts of two monoclonal 
antibodies (provided by Bayer Diagnostics).  Each antibody is directed to different 
regions on the beta subunit (one coupled to paramagnetic particles and the other labeled 
with DMAE) with specificity for intact FSH.  Inter- and intra-assay coefficients of 
variation were 12.0% and 6.0 %, respectively. 
 
Cross-validation of serum assays used in the Melbourne and SWAN Studies was 
conducted. Laboratories for each study received and analyzed samples from the other 
study. As neither measure can be defined as the gold standard, we created standardized 
values using an equating procedure (15) such that the standard scores (z scores) of the log 
FSH distribution from each assay are equated to each other. All analyses used these 
standardized FSH values.  
 
Using definitions recommended by WHO (16) and modified by ReSTAGE, a 
bleeding episode is a period of consecutive bleeding days; a bleeding-free interval is a 
period of consecutive bleeding free days; and a bleeding segment is a bleeding episode 
and the subsequent bleeding-free interval. In ReSTAGE, a single day of bleeding, as well 
as consecutive days of spotting/bleeding, were coded as bleeding episodes. Bleeding-free 
intervals had to consist of at least three days. One or two bleed-free days between two 
bleed days were considered part of the bleeding episode. Pregnancies and the first three 
segments post birth/abortion are considered nonmenstrual intervals and are excluded 
from analyses (17). For each bleeding segment, we indicate whether a woman was using 
hormone therapy or oral contraceptives, fertility medications, selective estrogen receptor 
modulators (SERMS), injectable contraceptives, contraceptive implants, or a short-course 
of hormones to treat a menstrual disorder.  Gaps in the menstrual record are coded as 
missing.    
 
This paper compares three recently proposed bleeding criteria (3, 18-20) for onset 
of the late menopausal transition with the current standard of 90-days of amenorrhea (5). 
We refer to the bleeding episode that marks when each criterion is met as the “marker 
event”, with age at occurrence defined as age on the first day of that bleeding episode.  
We calculated the following marker events: the first observed a) segment of at least 90-
days(3); b) segment of at least 60-days(20); c) skipped segment, defined as a segment 
that exceeded twice the median segment length of the previous 10 segments (3); and d) 
running range over a 10-segment sequence (18). For the running range, we identify the 
first day of the bleeding segment when the running range exceeds 42 days. Menopause is 
defined as the date of the FMP recorded in the menstrual calendars established 
retrospectively after 12 months of amenorrhea were observed.  
 
We created a dichotomous variable based on whether the woman reported 
experiencing any hot flashes (yes/no). In MWMHP, women were asked whether they had 
been bothered by hot flashes in the last two weeks. Originally scored on a 4 point scale 
(0=not present, 1=causes minor irritation, 2=interferes with normal life, 3=debilitating), 
we defined scores of 1-3 as having hot flashes. SWAN inquired about the presence of hot 
flashes in the past two weeks, with frequency originally indicated on a five point scale 
(0=not at all to 4=everyday). We defined scores of 1-4 as having hot flashes.  
Smoking status (current, former, never) is based on annual questionnaires. Body mass 
index (BMI) is based on a linear interpolation of annual height and weight measures, and 
categorized as <25, 25-29.9, 30-35, and >35.  
 
ANALYSIS  
Women were censored at hysterectomy, bilateral oophrectomy, initiation of 
hormonal birth control, hormone therapy or chemotherapy (Table 1). Segments during 
which a short-course of hormonal medication, including fertility medication, was used to 
treat a menstrual disorder were treated as gaps in the menstrual record.  
 
Ideally, we would have a gold standard against which to evaluate bleeding, FSH, 
and symptom criteria for onset of the late menopausal transition. In the absence of such a 
standard, we focus on how well bleeding criteria are associated with FSH and on how 
well each criterion alone versus bleeding criteria, FSH, and hot flashes predict FMP.  
Significance was defined by a p-value <0.05 in all analyses. 
 
We examined the association of FSH with each bleeding marker by estimating a 
binomial logistic regression model for each marker (has occurred, yes/no) as a function of 
log-transformed FSH, before and after adjusting for concurrent chronologic age,  baseline 
body mass index and baseline smoking status, and ethnicity in SWAN.  Within-woman 
correlation from multiple observations per woman was accounted for by using 
generalized estimating equations (21).  We tested interactions between log FSH and each 
covariates to determine whether associations between FSH and bleeding markers varied 
by subgroup.  From these models, we estimated the probability that a marker had 
occurred for various values of FSH. In addition, we computed odds ratios for marker 
occurrence in terms of categorized serum FSH.  Estimated probabilities of marker 
occurrence, done separately for each study, reflect not only the role of FSH but also the 
age distribution of each study.  In contrast, the odds ratios indicate the contribution of 
FSH apart from age.  
 
We used a Cox model to assess how well bleeding markers, serum FSH 
concentrations, and hot flash experience predict FMP. We started with a varying 
coefficient Cox model (22) where the marker effect on FMP varies with age at the marker 
event (23). Estimation proceeded using the regression spline method. Because the log 
hazard as a function of age at the marker event is approximately linear, the final 
regressions model the log hazard of the marker to FMP as a linear function of age at 
marker. These models were compared with corresponding models excluding FSH or hot 
flashes to assess the additional contributions of FSH and hot flashes in predicting the 
FMP. Potential confounding and interactions by smoking status, BMI and, within 
SWAN, by ethnicity, were examined. 
 
RESULTS 
 
Baseline characteristics of each study sample are summarized in Table 2.  
Reflecting eligibility criteria, MWMHP participants were older than SWAN participants. 
SWAN participants were heavier and MWMHP participants were less likely to have 
smoked.   
 
Serum FSH was strongly related to each of the bleeding markers in both studies 
(Figure 1).  The steepest increase in the marker probability occurred with an increase in 
FSH from 10 to 20 IU/L.  The curves for the 10-segment running range and a 60-day 
segment were similar to each other, particularly in the MWMHP dataset.  At any given 
FSH value, estimated probabilities for a skipped segment and a 90-day segment were 
lower.  Upon adjustment for age, the increase in the marker probability with an increase 
in FSH was less steep, but FSH remained significantly positively associated with each 
marker.  Further adjustment for covariates resulted in little additional change in the FSH 
associations with markers, and interactions of FSH with these covariates were not 
statistically significant (data not shown).  Associations were similar for SWAN and 
MWMHP.   
 Consistent with Figure 1, an increase in FSH was more strongly related to the 10-
segment running range and the 60-day segment than to the skipped segment, as seen in 
the larger odds ratios (Table 3).  The odds ratio was larger still for the 90-day segment. 
For all markers, odds ratios were highest for FSH >= 40 IU/L (versus < 10 IU/L). 
Adjustment for age reduced the magnitude of the FSH odds ratios such that only an FSH 
level greater than 40 IU/L was consistently associated with a statistically significant 
increased odds of experiencing each bleeding marker.  Results were similar for SWAN 
and MWMHP.   
 
Table 4 presents the relative hazard of FMP for serum FSH concentrations and 
hot flashes.. Cutpoints of 20-39 IU/L and >40 IU/L were selected based on Figure 1 and 
the published standards (23, 24). The likelihood of reaching the FMP increases with age, 
thus, the log-relative hazard of menopause for those women who have experienced a 
bleeding marker as compared with those who have not declines with age (20, 23). When 
considered alone, serum FSH concentrations greater than 20-39 IU/L were associated 
with a 2 to 4-fold increase in the log relative hazard of FMP, while values of 40 IU/L and 
above were associated with a 6-10 fold increase, although the confidence intervals are 
wide for both cutpoints and in both cohorts.  However, when serum FSH concentrations 
were considered jointly with bleeding markers, the effect of FSH is markedly attenuated, 
reflecting the associations of FSH with the bleeding markers seen in Figure 1 and Table 
3. In the MWMHP, the relative hazard of FMP was increased 4-fold when serum FSH 
concentrations were 20 IU/L or higher. In SWAN, which includes younger women and a 
shorter period of follow-up, a similar magnitude of effect was seen when serum FSH 
concentrations were 40 IU/L or higher.  The adjusted association between FSH and FMP 
varied little across models including different bleeding marker of the late transition. 
Annual serum FSH concentration provided additional information about which women 
were closest to menopause.  
Hot flashes, considered alone, were only weakly associated with the log relative 
hazard, and this association disappeared after adjustment for occurrence of a bleeding 
marker and serum FSH concentration. 
 
DISCUSSION 
This paper demonstrates that a single annual early follicular serum follicle-
stimulating hormone level is a marker of the late menopausal transition, but FSH 
concentrations are less predictive than any of the proposed bleeding criteria for the late 
menopausal transition (10). Moreover, when bleeding markers and FSH concentrations 
are considered together, the contribution of FSH is attenuated. Experience of hot flashes, 
while also a marker of the late menopausal transition in the absence of other hormonal or 
bleeding criteria, adds no information in the presence of these criteria. This paper also 
demonstrates that FSH is associated with both the bleeding criterion of 90-days of 
amenorrhea and of bleeding criteria based on shorter durations of amenorrhea, adding 
further evidence to support the STRAW recommendation that 60-days of amenorrhea be 
used as the criterion marker of the late menopausal transition. 
 Single annual serum follicle-stimulating hormone concentrations have been 
associated with the menopausal transition (25) as an indirect measure of the change in 
ovarian function that underpins reproductive aging, but they have not been rigorously 
related to well-defined bleeding markers of menopausal stage (5). FSH levels were 
qualitatively included in the STRAW model for reproductive aging (9), but specific 
cutpoints were not specified given the absence of a well-defined relationship between 
FSH concentrations and onset of the transition.  
 
Specification of cutpoints for annual serum FSH levels that might serve as criteria 
for onset of the menopausal transition has been problematic due to the variable pattern of 
FSH secretion, the variation in available assays (26), and the independent effects of age, 
body size and other variables (27). Cutpoints in this analysis reflect clinically utilized 
values but should not be construed as having specific intrinsic biological implications. 
We found that an annual serum FSH concentration of 40 IU/L is informative across both 
studies and could clearly be incorporated in conjunction with bleeding markers into the 
STRAW paradigm. In MWMHP there was no difference between the cutpoints 20 IU/L 
and 40 IU/L. In SWAN, 20 IU/L was less predictive than 40 IU/L. SWAN includes 
younger women and women who have transitioned earlier suggesting that the higher FSH 
values may be most predictive of women who transition faster or at a younger age. 
MWMHP includes older women who have all transitioned, suggesting that FSH over 20 
IU/L may be more informative for older women whereas an FSH level over 40 IU/L may 
be more informative for younger women.  Future analyses will evaluate whether 
algorithms for predicting the FMP should employ age-specific FSH cutpoints.  
 
Bleeding markers are most informative of a woman being in the late menopausal 
transition (20, 22, 23), but several competing criterion are currently proposed (20, 23). 
FSH levels are less informative but do add to the predictability of time to FMP. The 
additional information provided by serum FSH concentrations is similar regardless of the 
choice of bleeding criteria, suggesting that the ovarian biology underlying these changes 
in menstrual bleeding is the same for all of the proposed bleeding criteria for the late 
menopausal transition. Thus, selection of an optimal bleeding marker should be based on 
considerations such as frequency of occurrence, association with time to FMP, and ease 
of measurement.  
 
Follicle-stimulating hormone stimulates folliculogenesis and estradiol (E2) 
production in the ovary, and is regulated primarily in a classic negative feedback loop by 
the inhibins A and B secreted by the corpus luteum and follicle, respectively (14, 25, 28, 
29), and to a lesser extent by E2. As oocyte competence and the total number of ovarian 
follicles declines with age, negative feedback decreases as reflected in a progressive rise 
in FSH initially in the early phase of the menstrual cycle (25, 30). In both cross-sectional 
(7, 27) and longitudinal (25, 31, 32) studies of the menopausal transition, single measures 
of these biomarkers have substantial variability but increases in Inhibin B and FSH are 
observed before decreases in E2 (14, 25, 32). Widespread use of the Inhibin B measure 
has been precluded by cost and sensitivity of the assay (33). Assays of FSH vary by as 
much as two-fold (26), making comparisons between studies problematic and the 
establishment of criteria concentrations as reliable markers of transition stages difficult. 
These difficulties have been overcome in the current analysis by the similarities of the 
study design and subject populations, and by cross-validation of the FSH assay in the 
respective laboratories (15).  
 
The association of FSH with the bleeding markers is expected since bleeding 
markers are the clinical reflection of the underlying utero-ovarian biology. Given the 
variability of annual serum measures of FSH, bleeding markers may be most informative 
in the late menopausal transition as they reflect the cumulative impact of a changing 
hormonal environment including the most biologically significant changes in FSH. As 
such, they remain the most clinically significant markers of the late transition. Serum 
FSH may be a more important marker for the early menopausal transition when bleeding 
markers are less predictive of FMP, and future analyses of the ReSTAGE collaboration 
will address this question (34). 
 
 
  Self report of hot flashes has also been associated with the menopausal transition 
(5, 35, 36) and serum FSH levels (37), and is independently informative in the absence of 
any other marker of the late transition, albeit only modestly. However, when either FSH 
level or any bleeding marker is available, reported hot flashes do not add additional 
information regarding the likelihood of being in the late transition.  
 
This analysis has some limitations. Both studies set a lower age limit for 
enrollment and excluded women who were not still menstruating, so we can not evaluate 
whether FSH concentrations are more or less relevant for women with an earlier onset of 
the late menopausal transition. Moreover, SWAN is still in progress and not all women 
have completed their reproductive transition. Nonetheless, the results are notably robust, 
and support recommendations regarding the modification of the STRAW paradigm to 
include an annual serum FSH concentration of > 40 IU/L as an additional criterion for the 
late menopausal transition.  
 
In summary, we have shown that that a single annual early follicular serum 
follicle-stimulating hormone level is positively associated with four bleeding markers of 
the late menopausal transition, and is an independent but less robust marker of the late 
transition. Hot flashes are similarly positively associated with the late transition, but are 
much less robust and are no longer significant when considered together with FSH and 
bleeding markers. Thus, serum FSH levels should be incorporated into classification 
criteria for the late menopausal transition. 
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Table 1: Distribution of women by final menstrual period (FMP), and reasons for 
censoring in SWAN and MWMHP.  
 
 MWMHP 
(n=189) 
SWAN+  
(n=2256) 
Final Status N % N % 
FMP observed  45 23.8% 159 7.1% 
Hysterectomy 11 5.8% 42 1.9% 
Still menstruating 57 30.2% 1532 67.9% 
Stopped maintaining 
calendar although still 
menstruating  
51 27.0% 271 12.0% 
Endometrial Ablation 3 1.6% 0 0 
Began Using 
Hormone Therapy 
22 11.6% 252 11.2% 
+ Analysis to date of the SWAN calendar is based on the first  
   6 years of menstrual calendar data.  
Table 2: Characteristics of participants in the analytic sample. 
 
 SWAN (N=2256) MWMHP (N=189) 
Characteristic % (N) Mean (SD) % (N) Mean (SD) 
Age at entry  46.0 (2.5)  48.8 (2.0) 
Ethnicity:     
  African 
American 
23.4 (527)  0.0 (0)  
  Caucasian 50.7 (1144)  100.0 (189)  
  Chinese 9.3 (210)  0.0 (0)  
  Hispanic 6.1 (137)  0.0 (0)  
  Japanese 10.6 (238)  0.0 (0)  
Hormone use / 
fertility meds 
during study: 
    
  No 76.0 (1714)  81.5 (154)  
  Yes 24.0 (542)  18.5 (35)  
Body mass 
index (kg/m2) at 
study entry: 
 27.5 (6.9)  25.7 (4.7) 
  < 25 43.6 (984)  54.0 (102)  
  25 – 29.9 25.1 (566)  30.7 (58)  
  30 – 35  14.2 (321)  9.5 (18)  
  > 35 13.9 (313)  5.8 (11)  
  Unknown 3.2 (72)  0.0 (0)  
Smoking status 
at study entry: 
    
  Never 59.8 (1350)  63.0 (119)  
  Past 13.8 (311)  19.1 (36)  
  Current 25.6 (577)  18.0 (34)  
  Unknown 0.8 (18)  0.0 (0)  
 
 
 
 
 
 
 
 
Table 3: Estimated associations of serum FSH with occurrence of late-stage bleeding 
markers from repeated measures logistic regression, after adjustment for age. 
 
 
 Age-adjusted Odds Ratio (95% CI) for occurrence of marker 
Marker SWAN MWMHP 
RR10:   
  FSH < 10 IU/L Reference Reference 
  10 – 19.9 IU/L 1.01 (0.90, 1.15) 0.99 (0.59, 1.67) 
  20 – 39.9 IU/L 1.39 (1.21, 1.61) 1.36 (0.76, 2.42) 
  40+ IU/L 2.89 (2.45, 3.40) 3.65 (2.07, 6.44) 
VLS60:   
  FSH < 10 IU/L Reference Reference 
  10 – 19.9 IU/L 0.96 (0.85, 1.08) 0.99 (0.59, 1.66) 
  20 – 39.9 IU/L 1.37 (1.19, 1.57) 1.26 (0.72, 2.19) 
  40+ IU/L 2.81 (2.40, 3.31) 3.41 (1.89, 6.13) 
SS:   
  FSH < 10 IU/L Reference Reference 
  10 – 19.9 IU/L 1.05 (0.92, 1.19) 0.63 (0.39, 1.02) 
  20 – 39.9 IU/L 1.34 (1.16, 1.56) 0.88 (0.50, 1.55) 
  40+ IU/L 2.10 (1.78, 2.49) 2.17 (1.23, 3.83) 
VLS90:   
  FSH < 10 IU/L Reference Reference 
  10 – 19.9 IU/L 0.94 (0.79, 1.11) 1.11 (0.62, 1.98) 
  20 – 39.9 IU/L 1.48 (1.23, 1.78) 1.70 (0.99, 2.92) 
  40+ IU/L 4.10 (3.36, 5.01) 3.49 (1.97, 6.19) 
 
All associations of categorized serum FSH with marker occurrence, before and after adjustment for age, are 
statistically significant (p<0.0001)
Table 4: Relative Hazard of reaching FMP by serum FSH concentration and hot flash, 
unadjusted and adjusted for occurrence of bleeding markers of the late transition and 
BMI.  
 
 SWAN MWMHP 
 
Models 
Relative     95 % Confidence 
Hazard       Limits 
Relative   95%Confidence 
Hazard     Limits 
   
FSH 20-39   2.43          1.38, 4.25 4.44         1.53, 12.90 
FSH 40+  10.66          6.56, 17.31 6.76         2.53, 18.1 
   
Hot flash  1.91           1.35, 2.71 1.62         0.78, 3.34 
   
Adjusted Model*   
With >=60-day segment   
FSH 20-39 IU/L 1.59            0.90   2.80 5.01         1.66, 15.10 
FSH 40+  IU/L 3.44            2.09   5.66 2.80         1.03,  7.57 
Hot flash 1.24            0.86   1.78 0.92         0.51,  2.57 
   
   
With >=90-day segment   
FSH 20-39 IU/L 1.54             0.87,  2.71 4.09         1.39, 12.10 
FSH 40+ IU/L 2.83            1.69,   4.74 3.51         1.28,  9.65 
Hot flash 1.22             0.82,  1.75 1.37         0.65,  2.89 
   
With skipped segment   
FSH 20-39  IU/L 1.88             1.08, 3.28 4.82         1.65, 14.06 
FSH 40+ IU/L 5.51             3.36, 9.02 4.29         1.56, 11.82 
Hot flash 1.42             0.99, 2.03 1.49         0.70,  3.18 
   
With 10-segment  
running range 
  
FSH 20-39  IU/L 1.60              0.91,  2.80 4.47         1.51,13.27 
FSH 40+ IU/L 3.63              2.21,  5.94 3.36         1.24,  9.13 
Hot flash 1.21              0.84,  1.73 1.22         0.56,  2.64 
* adjusted for BMI and age at marker 
 Figure 1: Estimated unadjusted associations between bleeding markers and annual 
serum FSH concentrations. 
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Estimated unadjusted associations 
between bleeding markers and FSH
Melbourne longitudinal data (189 women)
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